Drug Profile
LEZ 763
Alternative Names: LEZ-763Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class Antihyperglycaemics
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 01 Sep 2013 Novartis completes a phase I/II trial in Type-2 diabetes mellitus in the US (NCT01619332)
- 20 Jun 2012 Phase-I/II clinical trials in Type-2 diabetes mellitus in USA (PO)